Matthew Eck

2 months ago | thecardiologyadvisor.com | Eve Makoff |Matthew Eck

Health care requires humanity. At its roots, narrative medicine embodies this ideology. Coined in 2000 by internist and scholar Rita Charon, MD, PhD, the field is “medicine practiced with the narrative competence to recognize, interpret, and be moved to action by the predicament of others.”1Without specific examples, however, narrative medicine can slip into a vague, abstract practice within the cultural consciousness.

Feb 28, 2025 | endocrinologyadvisor.com | Matthew Eck

In January and February, the Food and Drug Administration (FDA) expanded Ozempic® approval to include chronic kidney disease, approved the NovoLog® biosimilar MeriLog™, and issued an alert for diabetes-related smartphone device alerts. On January 28, the FDA expanded the approval of Ozempic (semaglutide) to reduce risk for worsening kidney disease, end-stage kidney disease, and death due to cardiovascular disease among patients with type 2 diabetes and chronic kidney disease.

Nov 15, 2024 | dermatologyadvisor.com | Eve Makoff |Matthew Eck

Health care requires humanity. At its roots, narrative medicine embodies this ideology. Coined in 2000 by internist and scholar Rita Charon, MD, PhD, the field is “medicine practiced with the narrative competence to recognize, interpret, and be moved to action by the predicament of others.”1Without specific examples, however, narrative medicine can slip into a vague, abstract practice within the cultural consciousness.

Oct 18, 2024 | endocrinologyadvisor.com | Matthew Eck |Lauren Edwards

This physician forum is the second part of a 2-part feature on the field of narrative medicine. The first part introduces narrative medicine theory and its application within the clinical setting. The following transcription of our physician forum has been edited for clarity and length. Matthew Eck: Hello, everyone. Welcome to today’s virtual forum, in which we will be discussing narrative medicine and its application in the clinical setting. My name is Matthew and I will be your moderator today.

Sep 23, 2024 | thecardiologyadvisor.com | Matthew Eck

Elevated interleukin-6 (IL-6) levels are associated with an increased risk for obesity-related cancers among patients recently diagnosed with type 2 diabetes, according to study results presented at the 60th Annual Meeting of the European Association for the Study of Diabetes, held from September 9 to 13, 2024 in Madrid, Spain.